No abstract

Two simple, rapid, accurate and economic spectrophotometric methods have been developed for the determination of Atenolol (ATE) & Lercanidipine Hydrochloride (LER) in combined dosage form. The first method is Area under curve (AUC) and second is Absorption Corrected method. The wavelength ranges 260-264 & 280-285 were selected to determine Atenolol (ATE) & Lercanidipine (LER), respectively in combined formulation by AUC method. The second method was absorption corrected method in which both the drugs exhibited strong absorbance at 270.33 nm. However, LER exhibited strong absorbance at 353.93, at which ATE showed zero absorbance. Hence, 353.93 nm was selected as one wavelength for determination of LER without interference from ATE. Quantitative estimation of ATE was carried out by subtracting the absorption due to LER at 270.33 nm using experimentally calculated absorption factor. Beer's law was obeyed in the concentration range of 25-300 ì g/ml for ATE and 5-60 ì g/ml for LER for both the methods. The results of analysis have been validated statistically and recovery studies confirmed the accuracy and reproducibility of the proposed methods which were carried out by following ICH guidelines.

Halogenation O 0235 A Green Approach for Efficient α-Halogenation of β-Dicarbonyl Compounds and Cyclic Ketones Using N-Halosuccinimides in Ionic Liquids. -The ionic liquid [bmim]PF6 is shown to be an effective reaction medium for the α-halogenation of a variety of 1,3-dicarbonyl compounds and cyclic ketones with N-halosuccinimides. -(MESHRAM*, H. M.; REDDY, P. N.; VISHNU, P.; SADASHIV, K.; YADAV, J. S.; Tetrahedron Lett. 47 (2006) 6, 991-995; Div. Org. Chem., Indian Inst. Chem. Technol., Hyderabad 500 007, India; Eng.) -Mais 19-035

Lovastatin is a statin drug used to prevent and treat coronary heart disease and to treat high cholesterol. In the present study, oral disintegrating thin films (ODTs) of lovastatin were designed with a view to enhance patient compliance by solvent casting method. In the solvent casting method, Croscarmellose sodium (CCS) (2, 4 and 6 % w/w), Crospovidone (10 and 15% w/w) as superdisintegrants were used in different concentrations with Gelatin, Poly vinyl alcohol (PVA) as a film forming base for the formulation of oral disintegrating thin films of lovastatin. The prepared formulations of films were evaluated for film thickness measurement, folding endurance study, in-vitro disintegration time, in-vitro drug release pattern and drug content. FTIR spectroscopy used to study drug-polymers interaction. Among all formulations, the formulation (F8) prepared by 4% crospovidone show enhanced drug release (99.27%) and it showed good stability for period of three months. Conclusively, the present study documents the development of a commercially viable formula lovastatin ODTs with rapidity in reducing heart problems.